Summary of Celcuity's Fireside Chat at TD Cowen's 46th Annual Healthcare Conference Company Overview - **Company**: Celcuity - **Focus**: Clinical-stage biotechnology company developing drugs targeting the PAM pathway, specifically the PI3K/AKT/mTOR pathway, which is crucial in oncology [3][3]. Key Trials and Developments - **Ongoing Trials**: - **Phase 3 Trial**: Evaluating Gedatolisib in combination with palbociclib and fulvestrant for women who have progressed on prior CDK therapy [3][3]. - **First-Line Study**: Same drug combination for treatment-naive women with endocrine-resistant metastatic breast cancer [3][3]. - **Earlier Phase Study**: Investigating Gedatolisib with an androgen receptor inhibitor in men with castration-resistant prostate cancer [3][3]. Regulatory Insights - **RTOR Designation**: Celcuity received Real-Time Oncology Review (RTOR) designation, which allows for early submission of data to the FDA, potentially shortening approval timelines for supplemental NDAs [11][11]. - **PDUFA Date**: The priority review is expected to conclude six months after the NDA acceptance, with expectations aligned with historical outcomes for similar drugs [12][12]. Launch Preparation - **Commercial Strategy**: A comprehensive launch plan has been in place for two years, focusing on building a commercial team and infrastructure across various departments [21][21][22][22]. - **Sales Force**: The hiring of sales representatives is expected to begin in the second quarter, aligning with the anticipated launch of Gedatolisib [22][22]. Market Segmentation and Patient Focus - **Target Patient Population**: The primary focus will be on PIK3CA wild type patients, constituting approximately 60% of the market. Data on mutant cohorts will be available prior to the launch, which could enhance market positioning [28][28]. - **Market Dynamics**: Celcuity anticipates a competitive landscape, particularly in the 20% of the market with ESR1 mutations, but believes it holds a significant advantage in the remaining 80% [78][78]. Efficacy and Safety Profile - **Efficacy Expectations**: The company aims for a median progression-free survival (PFS) of at least 10 months, which is statistically significant compared to existing treatments [43][43][45][45]. - **Safety Profile**: Gedatolisib shows a favorable safety profile with low rates of hyperglycemia (less than 10% overall, 2% grade three), contrasting sharply with competitors like alpelisib, which has an 80% hyperglycemia rate [64][64][66][66]. Financial Projections - **Revenue Potential**: Celcuity estimates a potential peak revenue exceeding $10 billion from Gedatolisib in breast cancer treatment, highlighting the significant market opportunity [95][95]. Conclusion - **Underappreciated Aspects**: The size of the patient population eligible for treatment and the potential impact of an effective drug targeting critical disease drivers are seen as key factors that could reshape investor perceptions [96][96].

Core Insights - The PEAK trial is the first study to show statistical significance over an active comparator in GIST patients, with the combination of bezuclastinib and sunitinib achieving a median progression-free survival (mPFS) of 16.5 months and an overall response rate (ORR) of 46% in patients previously treated with imatinib [1][2] Group 1: FDA Approval and Clinical Trial Results - The FDA has accepted Cogent Biosciences' New Drug Application (NDA) for bezuclastinib in combination with sunitinib for GIST patients who have received prior treatment with imatinib under the Real-Time Oncology Review (RTOR) program [1][4] - The bezuclastinib combination demonstrated a 50% reduction in the risk of disease progression or death compared to the current standard of care, with a hazard ratio of 0.50 (95% CI: 0.39 – 0.65) [2] - The mPFS for the bezuclastinib combination was 16.5 months compared to 9.2 months for sunitinib monotherapy, and the ORR was 46% for the bezuclastinib combination versus 26% for sunitinib [2] Group 2: Safety and Future Plans - The bezuclastinib combination was generally well tolerated, with no unique risks observed compared to the known safety profile of sunitinib [3] - Cogent plans to present full results from the PEAK trial at a major medical meeting in the first half of 2026 and will initiate a Phase 2 trial in mid-2026 for first-line GIST patients with exon 9 mutations [5][8] Group 3: Company Overview - Cogent Biosciences is focused on developing precision therapies for genetically defined diseases, with bezuclastinib being a selective tyrosine kinase inhibitor targeting the KIT D816V mutation and other mutations in KIT exon 17 [6] - The company is also developing a portfolio of targeted therapies aimed at various mutations, including FGFR2/3, ErbB2, PI3Kα, KRAS, and JAK2 [6]